News
Regeneron to buy bankrupt 23andMe, vows ethical use of customer DNA data
Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from customers using ancestry testing and other services.
States take legal action as 23andMe attempts to sell customer genetic information amid bankruptcy
Twenty-seven states and the District of Columbia took legal action this week against 23andMe in the U.S. Bankruptcy Court for the Eastern District of Missouri, the court overseeing the Chapter 11 bankruptcy proceedings that the genetic testing company entered earlier in the year.
The future of the genetic data owned by 23andMe is uncertain as the company undergoes a court-supervised sale.
1don MSN
Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, ...
Bankrupt DNA testing company 23andMe Holding (OTC:MEHCQ) is set to hold a second auction to sell its assets, including ...
WilmerHale said it’s representing the law professor tapped to make privacy-related recommendations about the sale of ...
New York and 27 other states sued bankrupt genetic testing company 23andMe to block the sale of 15 million customers' ...
Lawmakers want to know what will be done to make sure consumer genetic testing company 23andMe’s data will stay out of the ...
D.C. sue to block 23andMe's data sale amid bankruptcy proceedings. Regeneron Pharmaceuticals' $256 million acquisition faces ...
Me is now facing a multi-state lawsuit that seeks to block the genetic testing company from selling data without "explicit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback